BioTuesdays

Adamas Pharma names Neil McFarlane as CEO

Adamas Pharmaceuticals (NASDAQ:ADMS) has appointed Neil McFarlane as CEO and a member of its board, effective Sept. 16. Gregory Went, Adamas’ founder, chairman and CEO, will transition to a strategic advisory role...

Roth starts Cellectar Biosciences at buy; PT $11

Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted...

BTIG ups Eidos Therapeutics PT to $56 from $38

BTIG raised its price target for Eidos Therapeutics (NASDAQ:EIDX) to $56 from $38 after a committee of the board unanimously rejected a share exchange offer from its parent company, BridgeBio Pharma, (NASDAQ:BBIO) to...

T2 Biosystems

Analysts up T2 Biosystems price targets

Analysts for Alliance Global Partners and SVB Leerink raised their price targets for T2 Biosystems (NASDAQ:TTOO) following a conference call that updated multiple positive developments. Ben Haynor of AGP writes that the...

Subscribe

Sign up to our weekly BioTuesdays newsletter.